作者
María José Solís Marín,Ricardo Arturo Vargas Fernández,María Nicole Aguilar Cordero,Boris Fernández Barrantes,Oswaldo Gabriel Ruiz Arce,Daniel Ramírez Aguilar
摘要
Persistent human papillomavirus infection is a multifactorial process shaped by viral, host, and environmental determinants that collectively promote immune evasion, persistence, and malignant progression. Infection begins in the basal epithelial cells, where viral attachment and entry are mediated by specific host receptors, followed by maintenance of viral DNA as episomes or, in some cases, integration into the host genome. This integration frequently disrupts viral regulatory genes and leads to overexpression of the E6 and E7 oncoproteins, which inactivate p53 and retinoblastoma protein, promote telomerase activation, and drive genomic instability. These events establish the molecular basis for cell immortalization and carcinogenesis. A central feature of persistent infection is the ability of human papillomavirus to evade both innate and adaptive immunity. The virus limits immune detection through low-copy replication, minimal cytopathic effects, suppression of interferon signaling, impairment of antigen-presenting cells, and evasion of natural killer cell activity. At the adaptive level, defective cytotoxic T cell responses, T helper imbalance, regulatory T cell infiltration, and T cell exhaustion further weaken viral clearance. Humoral immunity is also limited during natural infection, explaining why established infections are often not effectively eliminated. As persistence continues, oncogenic signaling pathways, genomic instability, and local immunosuppressive tumor microenvironments facilitate progression from intraepithelial neoplasia to invasive carcinoma. This process is influenced by genetic susceptibility, hormonal factors, microbiome alterations, immunosuppression, coinfections, and behavioral cofactors. Although prophylactic vaccines provide strong protection against new infections, established disease still requires therapeutic approaches such as therapeutic vaccines, immune checkpoint inhibitors, and emerging cell-based and viral immunotherapies.